Answers are grounded in this paper and cite their sources.
As the therapeutic RNA field celebrates a watershed year in 2026—marked by milestone clinical readouts in linear mRNA cancer vaccines, chronic monogenic conditions, and circular RNA in vivo cell engineering—the global biopharmaceutical ecosystem is facing a profound structural realignment. Just as scientific delivery platforms are maturing to cross traditional biological barriers, international policy is erecting new borders. Recent regulatory drafts from Beijing—specifically revisions to China’s technology export controls under announcement no.
No takes yet. Share an insight, caveat, or question.
Nitto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: